Phase 2 N=224 Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With a Clinical Response at Week 8 — 33; 45; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
End Stage Renal Disease · Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) and the Number of TEAEs Will be Summarized Using Frequency Counts (Safety and Tolerability) — 0; 0…
Phase 2 N=33 Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 26; 5; 4; 0 Participants
Phase 2 N=567 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Heavy Uterine Bleeding · Uterine Fibroids
Primary: Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month…
Phase 2 N=117 Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 5.8; 8.1 months — p=0.8956
Phase 2 N=101 A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Lymphoma
Primary: Progression-Free Survival (PFS) Time — 36.2; 22.6 months
Phase 2 N=20 Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients
COVID-19
Primary: Number of Participants With Early Viral Clearance — 5; 4; 1; 0 Participants
Phase 2 N=26 A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Colorectal Tumor
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate) — 26; 23 percentage of participants — p=0.431
Phase 2 N=50 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Primary: The Primary Outcome Will be Improvement in Hepatic Steatosis by Liver MRI — 17.9; 14.2 % of fat
Phase 2 N=9 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Phase 2 N=834 A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -0.18; -1.01; -1.22; -1.09 percentage — p=<0.001
Phase 2 N=397 Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
Hookworm Infections
Primary: Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against Hookworm — 68.5; 70.8 percentage change in hookworm egg counts
Phase 2 N=23 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Progression-Free Survival (PFS) — 6.05; 5.26 months — p=0.058
Phase 2 N=20 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 29.5; 25.1 MEq/min — p=0.8
Phase 2 N=49 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
Lung Cancer
Primary: AUC Value Symptom Severity Differences — 31.18; 44.98; 17.13; 26.64 Units on a scale *week